Updated Breyanzi® labeling: Reduced post-infusion monitoring period, reduced post-treatment driving restrictions, and REMS removal make
Breyanzi accessible to more patients. Learn more >

Breyanzi is THE ONE CAR T for the broadest range of R/R B-cell malignancies

Breyanzi is the one CAR T to bring hope for remission to more patients

Select an indication to find efficacy and safety data, dosing and administration
information, and resources for you and your patients.

R/R Large B-Cell Lymphoma (LBCL)

3L+ Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

3L+ Follicular Lymphoma (FL)

3L+ Mantle Cell Lymphoma (MCL)

*Please see the full indications and limitations of use further below.

Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring.1

3L, third-line; CAR, chimeric antigen receptor; R/R, relapsed or refractory.

Reference

  1. Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025.


Bristol Myers Squibb logo

© 2025 Juno Therapeutics, Inc., a Bristol Myers Squibb company. All Rights Reserved.
BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.
Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

© 2025 Bristol Myers Squibb company.

2009-US-2500222

09/2025